Free Newsletter
FDA selects flu strains for next round of vaccines
The FDA has come up with a lineup of three all-new flu strains for this year's vaccine recipe. Typically, only one or two strains are changed, but health officials felt that following last season's ineffective vaccine jab a new approach was called for.
It's not easy getting the strains right. Most vaccines are consistently effective against their targets. But the steadily changing nature of influenza makes it a tough target to hit. Inevitably, there's always a guessing game about which strains will be circulating during an upcoming flu season.
This season's list of manufacturers and approved vaccines (by way of the Washington Post): CSL Limited, Afluria; GlaxoSmithKline Biologicals, Fluarix; ID Biomedical, FluLaval; MedImmune Vaccines, FluMist; Novartis Vaccines and Diagnostics, Fluvirin; and Sanofi Pasteur, Fluzone.
- read the story from the Washington Post
Related Articles:
Flu jab missing the mark in seasonal campaign
Vaccines ineffective in seasonal flu campaign
Breakthrough reported in flu vaccine research
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A; Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
More Research Reports >>
